Market Research Logo

Gouty Arthritis (Gout) - Pipeline Review, H2 2015

Gouty Arthritis (Gout) - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Gouty Arthritis (Gout) - Pipeline Review, H2 2015’, provides an overview of the Gouty Arthritis (Gout)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Gouty Arthritis (Gout), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gouty Arthritis (Gout) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Gouty Arthritis (Gout)
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Gouty Arthritis (Gout) and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Gouty Arthritis (Gout) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Gouty Arthritis (Gout) pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Gouty Arthritis (Gout)
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Gouty Arthritis (Gout) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Gouty Arthritis (Gout) Overview
Therapeutics Development
Pipeline Products for Gouty Arthritis (Gout) - Overview
Pipeline Products for Gouty Arthritis (Gout) - Comparative Analysis
Gouty Arthritis (Gout) - Therapeutics under Development by Companies
Gouty Arthritis (Gout) - Therapeutics under Investigation by Universities/Institutes
Gouty Arthritis (Gout) - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Gouty Arthritis (Gout) - Products under Development by Companies
Gouty Arthritis (Gout) - Products under Investigation by Universities/Institutes
Gouty Arthritis (Gout) - Companies Involved in Therapeutics Development
AstraZeneca Plc
Celtaxsys, Inc.
CymaBay Therapeutics, Inc.
Delenex Therapeutics AG
Immune Response BioPharma, Inc.
IOmet Pharma
JW Pharmaceutical Corporation
LG Life Science LTD.
Monosol Rx, LLC
Nimbus Therapeutics, LLC
Omni Bio Pharmaceutical Inc.
Opsona Therapeutics Limited
PLx Pharma Inc.
Polaris Pharmaceuticals, Inc.
Selecta Biosciences, Inc.
Takeda Pharmaceutical Company Limited
Teijin Limited
TWi Pharmaceuticals, Inc.
Wellstat Therapeutics Corporation
Gouty Arthritis (Gout) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
acebilustat - Drug Profile
Product Description
Mechanism of Action
R&D Progress
arhalofenate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AXIBU-03 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
colchicine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
diacerein - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DLX-2323 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DLX-2681 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
FcAAT-2 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
FcAAT-3 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
febuxostat - Drug Profile
Product Description
Mechanism of Action
R&D Progress
febuxostat XR - Drug Profile
Product Description
Mechanism of Action
R&D Progress
IR-888 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LC-350189 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
lesinurad sodium - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Moniclonal Antibody to Inhibit S100A9 Protein for Neurodegenerative Diseases, Chronic Inflammation and Autoimmune Disorders - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ND-2110 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ND-2158 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ND-346 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pegadricase - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pegadricase - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PL-4100 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RDEA-3170 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Recombinant Enzyme for Gout and Tumor Lysis Syndrome - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Recombinant Protein to Replace Alpha-1 Antitrypsin Cardiovascular, Metabolic Disorders, Immunology, Gastrointestinal Disease - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RLBN-1001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RLBN-2020 Series - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RLBN-3010 Series - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule Inflammasome Modulator Programme - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Inhibit Xanthine Oxidase for Gout and Hyperuricemia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Inhibit GLUT9 for Gout - Drug Profile
Product Description
Mechanism of Action
R&D Progress
URC-102 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
uriSHELS - Drug Profile
Product Description
Mechanism of Action
R&D Progress
WT-2107 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
XEN-102 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
XEN-104 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gouty Arthritis (Gout) - Recent Pipeline Updates
Gouty Arthritis (Gout) - Dormant Projects
Gouty Arthritis (Gout) - Discontinued Products
Gouty Arthritis (Gout) - Product Development Milestones
Featured News & Press Releases
Nov 09, 2015: AstraZeneca Presents Positive Update on Lesinurad Renal Data in Gout Patients
Nov 05, 2015: CymaBay Therapeutics to Present Results From Two Arhalofenate Phase 2 Studies at the American College of Rheumatology Annual Meeting, November 6 - 11
Oct 23, 2015: FDA Advisory Committee recommends the approval of lesinurad for gout patients
Oct 19, 2015: MonoSol Rx Leadership Presents Data Supporting PharmFilm Technology Effective for Oral Peptide Delivery
Aug 06, 2015: CymaBay Strengthens the Intellectual Property of Arhalofenate With Issuance of Two New Patents
Jun 30, 2015: New Indication for Teijin Pharma’s Febuxostat in Europe
Jun 13, 2015: AstraZeneca Announces Phase III Results for Lesinurad in Combination with Febuxostat in Tophaceous Gout Patients at European League Against Rheumatism Annual Congress
Jun 12, 2015: CymaBay Therapeutics Presents Poster at EULAR 2015
Jun 10, 2015: Selecta Biosciences Initiates Phase 1 Clinical Program of SEL-212, Designed As the First Non-Immunogenic Biologic Treatment for Gout
Mar 23, 2015: CymaBay Therapeutics to Host Key Opinion Leader Meeting on March 27 in New York City
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Gouty Arthritis (Gout), H2 2015
Number of Products under Development for Gouty Arthritis (Gout) - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Comparative Analysis by Unknown Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Products under Investigation by Universities/Institutes, H2 2015
Gouty Arthritis (Gout) - Pipeline by AstraZeneca Plc, H2 2015
Gouty Arthritis (Gout) - Pipeline by Celtaxsys, Inc., H2 2015
Gouty Arthritis (Gout) - Pipeline by CymaBay Therapeutics, Inc., H2 2015
Gouty Arthritis (Gout) - Pipeline by Delenex Therapeutics AG, H2 2015
Gouty Arthritis (Gout) - Pipeline by Immune Response BioPharma, Inc., H2 2015
Gouty Arthritis (Gout) - Pipeline by IOmet Pharma, H2 2015
Gouty Arthritis (Gout) - Pipeline by JW Pharmaceutical Corporation, H2 2015
Gouty Arthritis (Gout) - Pipeline by LG Life Science LTD., H2 2015
Gouty Arthritis (Gout) - Pipeline by Monosol Rx, LLC, H2 2015
Gouty Arthritis (Gout) - Pipeline by Nimbus Therapeutics, LLC, H2 2015
Gouty Arthritis (Gout) - Pipeline by Omni Bio Pharmaceutical Inc., H2 2015
Gouty Arthritis (Gout) - Pipeline by Opsona Therapeutics Limited, H2 2015
Gouty Arthritis (Gout) - Pipeline by PLx Pharma Inc., H2 2015
Gouty Arthritis (Gout) - Pipeline by Polaris Pharmaceuticals, Inc., H2 2015
Gouty Arthritis (Gout) - Pipeline by Selecta Biosciences, Inc., H2 2015
Gouty Arthritis (Gout) - Pipeline by Takeda Pharmaceutical Company Limited, H2 2015
Gouty Arthritis (Gout) - Pipeline by Teijin Limited, H2 2015
Gouty Arthritis (Gout) - Pipeline by TWi Pharmaceuticals, Inc., H2 2015
Gouty Arthritis (Gout) - Pipeline by Wellstat Therapeutics Corporation, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Gouty Arthritis (Gout) Therapeutics - Recent Pipeline Updates, H2 2015
Gouty Arthritis (Gout) - Dormant Projects, H2 2015
Gouty Arthritis (Gout) - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Gouty Arthritis (Gout), H2 2015
Number of Products under Development for Gouty Arthritis (Gout) - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Routes of Administration, H2 2015
Number of Products by Stage and Routes of Administration, H2 2015
Number of Products by Molecule Types, H2 2015
Number of Products by Stage and Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report